Rhythm Pharmaceuticals, Inc.
RYTM
$104.99
-$8.75-7.69%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 48.31% | -21.82% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 48.31% | -21.82% | |||
| Cost of Revenue | 51.95% | -3.67% | |||
| Gross Profit | 47.85% | -23.62% | |||
| SG&A Expenses | 17.55% | 2.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.68% | -4.06% | |||
| Operating Income | 3.63% | -13.94% | |||
| Income Before Tax | 6.32% | -13.91% | |||
| Income Tax Expenses | 321.25% | 188.89% | |||
| Earnings from Continuing Operations | 5.79% | -14.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.79% | -14.34% | |||
| EBIT | 3.63% | -13.94% | |||
| EBITDA | 3.66% | -14.07% | |||
| EPS Basic | 6.51% | -11.22% | |||
| Normalized Basic EPS | 7.25% | -11.27% | |||
| EPS Diluted | 6.51% | -11.22% | |||
| Normalized Diluted EPS | 7.25% | -11.27% | |||
| Average Basic Shares Outstanding | 0.99% | 2.37% | |||
| Average Diluted Shares Outstanding | 0.99% | 2.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||